Both the rituximab dose and maintenance immunosuppression in steroid-dependent/frequently-relapsing nephrotic syndrome have important effects on outcomes
Eugene Yu-hin Chan(Chinese University of Hong Kong), Kjell Tullus(Great Ormond Street Hospital), Tomohiko Yamamura(Kobe University), Gian Marco Ghiggeri(Istituto Giannina Gaslini), Hazel Webb(National Health Service), Isaac Desheng Liu(National University Health System), Claire Dossier, Marina Vivarelli(Bambino Gesù Children's Hospital), Arvind Bagga(All India Institute of Medical Sciences), Aditi Sinha, Kenji Ishikura(Kitasato University), Koichi Kamei(National Center For Child Health and Development), E. Yu, Markus J. Kemper(University of Zurich), Priya Saini(Hospital for Sick Children)
Cited by 119
Related Papers
A Single-Gene Cause in 29.5% of Cases of Steroid-Resistant Nephrotic Syndrome
|Journal of the American Society of Nephrology|2014|660
The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4
|Nature Genetics|2006|573
SIX1 mutations cause branchio-oto-renal syndrome by disruption of EYA1–SIX1–DNA complexes
|Proceedings of the National Academy of Sciences|2004|420
Patients with Mutations in NPHS2 (Podocin) Do Not Respond to Standard Steroid Treatment of Nephrotic Syndrome
|Journal of the American Society of Nephrology|2004|415